Xiaoming Zhang

Xiaoming Zhang, PhD has 16 years of drug discovery and preclinical development experience. He was formerly Senior Director of Chemistry at CoMentis Inc. In this capacity, he led the alpha7 nicotinic acetylcholine receptor agonist program, which is currently in preclinical development for AD and cognitive deficit associated with schizophrenia. Previously, Dr. Zhang served as Director of Medicinal Chemistry at Millennium Pharmaceuticals, Portola and ARYx, where he successfully led the discovery and preclinical development of a number of new molecular entities, notably PRT060128 (elinogrel) and tecarfarin. Earlier in his career, Dr. Zhang was a research scientist at Roche Bioscience and later program leader in the Urology Therapeutic Area, where he successfully led the alpha1 adrenergic agonist backup program, culminating in the discovery of R1484 which reached Phase 1 for stress incontinence.

Dr. Zhang received a PhD from University of Maryland in the field of synthetic organic chemistry and pursued postdoctoral research at University of California, Berkeley. He is an inventor on 23 US patents and patent applications.